NASDAQ:PDSB

Pds Biotechnology Stock Insider Trading

Healthcare > Biotechnology

Buy PDSB

*Your capital is at risk

$1.08

-0.0800 (-6.90%)

At Close: Jun 03, 2026

PDS Biotechnology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 8.84M and sold 350.37K PDSB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	8.84M shares
● Sell	350.37K shares
98% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Sykes Richard Director	Director	9 000 Value: $25.7K
Jun 24, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Glover Stephen C. Director	Director	9 000 Value: $25.7K
Jun 24, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Freitag Gregory Gene Director	Director	9 000 Value: $25.7K
May 01, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Toutain Stephan Chief Operations Officer	Officer	200 000 Value: $722.0K
May 01, 2024 Buy	Common Stock J-Other	Toutain Stephan Insider	Other	0 Value: $0
May 01, 2024 Buy	Common Stock J-Other	Toutain Stephan Insider	Other	0 Value: $0
May 01, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Toutain Stephan Chief Operations Officer	Officer	200 000 Value: $722.0K
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Bedu-addo Frank President/ceo	CEO / President	300 000 Value: $1.76M
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Brown Spencer D. Senior Vp, General Counsel	Officer	56 000 Value: $328.7K
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Conn Gregory Chief Scientific Officer	Officer	46 648 Value: $273.8K
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Conn Gregory Chief Scientific Officer	Officer	46 648 Value: $273.8K
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Brown Spencer D. Senior Vp, General Counsel	Officer	56 000 Value: $328.7K
Feb 28, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Bedu-addo Frank President/ceo	CEO / President	300 000 Value: $1.76M
Jan 22, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Shepard Kirk V. Chief Medical Officer	Officer	200 000 Value: $898.0K
Jan 22, 2024 Buy	Common Stock J-Other	Shepard Kirk V. Insider	Other	0 Value: $0
Jan 22, 2024 Buy	Common Stock J-Other	Shepard Kirk V. Insider	Other	0 Value: $0
Jan 22, 2024 Buy	Employee Stock Option (Right to Buy) A-Award	Shepard Kirk V. Chief Medical Officer	Officer	200 000 Value: $898.0K
Dec 04, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Boesgaard Lars Chief Financial Officer	C-Suite Officer	200 000 Value: $1.06M
Dec 04, 2023 Buy	Common Stock J-Other	Boesgaard Lars Insider	Other	0 Value: $0
Dec 04, 2023 Buy	Common Stock J-Other	Boesgaard Lars Insider	Other	0 Value: $0
Dec 04, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Boesgaard Lars Chief Financial Officer	C-Suite Officer	200 000 Value: $1.06M
Jul 14, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Freitag Gregory Gene Director	Director	9 000 Value: $46.2K
Jul 14, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Brawley Otis W Director	Director	9 000 Value: $46.2K
Jul 14, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Ali-jackson Kamil Director	Director	9 000 Value: $46.2K
Jul 14, 2023 Buy	Employee Stock Option (Right to Buy) A-Award	Sykes Richard Director	Director	9 000 Value: $46.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PDS BIOTECHNOLOGY CORP.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclini...

Read Full Profile Here